Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Purpose
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Conditions
- Breast Cancer
- Metastatic Breast Cancer
- Breast Neoplasm
- Breast Cancer Metastatic
- End Stage Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Be ≥ 18 years of age. 2. Have signed informed consent. 3. Have histological confirmation of breast cancer with either locally recurrent unresectable and/or metastatic lesions, and have failed prior therapy: - Patients with persistent disease and local recurrence must not be amenable to local treatment. - For patients with metastatic disease, late-stage MBC with no meaningful alternative therapies available and the following class specific treatment histories: 1. Human epidermal growth factor 2 (HER2) positive must be previously treated with at least 3 regimens containing at least two anti-HER2 and at least one chemotherapy containing regimen. 2. Estrogen receptor (ER), progesterone receptor (PR) positive tumors: must be refractory to hormonal therapy demonstrated by progression on at least 2 hormonal agents in 2 separate lines of hormone directed therapy. 3. Triple Negative tumors: Must have exhausted all curative intent therapies including at least 2 prior chemotherapy regimens, which can include regimens in neoadjuvant and adjuvant settings. 4. Cancers with known germline or genomic actionable targets, e.g. g/mBRCA, must have been treated with all tumor directed indicated treatment e.g. PARPi, if tolerated. 5. HER2 low patients, in addition to the appropriate therapies based on ER/PR status and germline or genomic actionable targets, must also have received at least one HER2-targeted agent approved for treatment of HER2 low patients. 6. HER2 negative tumors must be refractory to hormonal therapy (if indicated) and previously treated with at least 2 chemotherapy regimens. 7. Patients with new or progressive breast cancer metastatic to the brain will be eligible provided: - The brain metastases must be clinically stable (without evidence of progressive disease by imaging for at least 4 weeks prior to first dose) - There is no need for steroids and patients have not had steroids for at least 2 weeks prior to the first dose - Tumor is not impinging on Middle Cerebral Artery/speech-motor strip - If surgically debulked, must be healed with at least 3 weeks since surgery prior to the first dose 4. Has expected survival of at least 4 months. 5. ECOG performance status of 0, 1 or 2
Exclusion Criteria
- Concurrent or recent chemotherapy, immunotherapy or major surgery within 21 days prior to the first dose. 2. Radiotherapy within 14 days of the first dose of study treatment. 3. Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion support). 4. Any toxicity to prior CPI that was grade 3 or higher unless it has been successfully treated (e.g. hypothyroidism or hypopituitarism treated with replacement therapy), . 5. Toxicity to prior CPI that has not resolved to grade 1 or less except for stable asymptomatic endocrinopathies. 6. History of clinical hypersensitivity to the designated therapy as specified in the protocol, including the proposed TPC, beef, or to any components used in the preparation of SV- BR-1-GM. 7. History of hypersensitivity to any of the therapies proposed for treatment in this study. 8. Serum creatinine OR Measured OR calculated Creatinine Clearance (CrCl) (GFR can also be used in place of creatinine or CrCl) >2.0 × ULN or <30 mL/min for participants with creatinine levels >2.0 × institutional ULN. 9. Absolute granulocyte count <1000; platelets <80,000; hemoglobin ≤ 7 g/L. 10. Bilirubin ≥ 2 × ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >3x ULN. For patients with hepatic metastases, ALT/AST >5x ULN is exclusionary. 11. INR or PT or aPTT > 1.8 × ULN, unless the participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants. 12. Receiving any medication listed in the prohibited medication section of the protocol. 13. Proteinuria >2+ on urinalysis 14. A history or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful. Screening corrected QT interval (QTc) interval >480 milliseconds is excluded (corrected by Fridericia or Bazett formula). In the event that a single QTc is >480 milliseconds, the participant may enroll if the average QTc for the 3 ECGs is <480 milliseconds. 15. New York Heart Association stage 3 or 4 cardiac disease. 16. A pericardial effusion of moderate severity or worse. 17. Symptomatic pleural effusion or ascites. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible. 18. Any woman of childbearing potential (i.e., has had a menstrual cycle within the past year and has not been surgically sterilized), unless she agrees to take appropriate precautions to avoid becoming pregnant during the study and has a negative serum pregnancy test within 7 days prior to starting treatment. 19. Men must have been sterile or, if they were potentially fertile/reproductively competent, should take appropriate precautions to avoid fathering a child for the duration of the study. 20. Women who are pregnant or nursing. 21. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent. 22. Patients who have uncontrolled HIV or have clinical or laboratory features indicative of AIDS. 23. Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. 24. Have an active autoimmune disease that has required systemic treatment in past year (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed. 25. Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization). 26. Active infections requiring systemic therapy within the past 14 days. 27. Patients with severe psychiatric disease (e.g., schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator in consultation with the Medical Monitor. 28. Has received a live vaccine within 28 days of the first dose of study drug. 29. Patients may not be on a concurrent clinical trial, unless approved by the Investigator.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Bria-IMT Regimen + CPI |
The Bria-IMT regimen: Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site |
|
|
Active Comparator Treatment of Physician's Choice |
TPC consists of eribulin, carboplatin, capecitabine, gemcitabine, vinorelbine or taxanes in accordance with the investigators' and institutional standard of care. The specific details of the selected regimen must include every detail of administration including frequency, sequencing (for multi-agent regimens), duration of infusion or oral administration, planned dose, dose prescribed, dose administered, dose adjustments after initial prescription or start of TPC treatment, and any other change in TPC from its initial election prior to randomization. |
|
|
Experimental Bria-IMT Regimen Alone |
The Bria-IMT regimen: Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon administered intra-dermally within each SV-BR-1-GM inoculation site |
|
Recruiting Locations
Los Angeles cancer Network_Anaheim
Anaheim, California 92801
Anaheim, California 92801
Comprehensive Blood and Cancer Center
Bakersfield, California 93309
Bakersfield, California 93309
Los Angeles Cancer Network_Corona
Corona, California 92879
Corona, California 92879
Los Angeles cancer Network_Fountain Vallley
Fountain Valley, California 92708
Fountain Valley, California 92708
Los Angeles Cancer Network_Glendale
Glendale, California 91206
Glendale, California 91206
Los Angeles Cancer Network
Los Angeles, California 90017
Los Angeles, California 90017
Los Angeles Cancer Network_Century City
Los Angeles, California 90067
Los Angeles, California 90067
Los Angeles Cancer Network_Pasadena
Pasadena, California 91105
Pasadena, California 91105
Los Angeles cancer Network_Riverside
Riverside, California 92501
Riverside, California 92501
St. John's Cancer Center
Santa Monica, California 90404
Santa Monica, California 90404
Torrance Memorial Cancer Center
Torrance, California 90505
Torrance, California 90505
Los Angeles Cancer Network_Valley Pres
Van Nuys, California 91405
Van Nuys, California 91405
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut 06511
New Haven, Connecticut 06511
University of Miami-SCCC-Lennar
Coral Gables, Florida 33146
Coral Gables, Florida 33146
University Of Miami-SCCC-Miami
Miami, Florida 33136
Miami, Florida 33136
Advent Health - Orlando
Orlando, Florida 32804
Orlando, Florida 32804
University of Miami-SCCC-Plantation
Plantation, Florida 33324
Plantation, Florida 33324
Northwestern University
Chicago, Illinois 60611
Chicago, Illinois 60611
Southern Illinois University-Simmons
Springfield, Illinois 62702
Springfield, Illinois 62702
Carle Foundation Cancer Institute-Urbana
Urbana, Illinois 61801
Urbana, Illinois 61801
Northwest Cancer Center
Dyer, Indiana 46311
Dyer, Indiana 46311
AMR Kansas City Oncology
Kansas City, Kansas 66204
Kansas City, Kansas 66204
Care Access-Marrero
Marrero, Louisiana 70072
Marrero, Louisiana 70072
The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A.
Bethesda, Maryland 20817
Bethesda, Maryland 20817
Nebraska Cancer Specialists
Omaha, Nebraska 68130
Omaha, Nebraska 68130
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Babylon)
Babylon, New York 11702
Babylon, New York 11702
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (Brox)
Bronx, New York 10469
Bronx, New York 10469
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(New Hyde Park)
New Hyde Park, New York 11042
New Hyde Park, New York 11042
Manhattan Hematology /Oncology Associates
New York, New York 10016
New York, New York 10016
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY)
New York, New York 10028
New York, New York 10028
New York Cancers & Blood Specialists_North Shore Hematology Oncology Assocaites P.C (Patchogue)
Patchogue, New York 11772
Patchogue, New York 11772
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2)
Port Jefferson Station, New York 11776
Port Jefferson Station, New York 11776
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1)
Port Jefferson Station, New York 11776
Port Jefferson Station, New York 11776
New York Cancers & Blood Specialists
Port Jefferson Station, New York 11776
Port Jefferson Station, New York 11776
New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Riverhead)
Riverhead, New York 11901
Riverhead, New York 11901
Gabrail Cancer & Research Center
Canton, Ohio 44718
Canton, Ohio 44718
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas 75246
Dallas, Texas 75246
Mary Crowley Cancer Research
Dallas, Texas 75251
Dallas, Texas 75251
DHR Health Oncology Institute
Edinburg, Texas 78539
Edinburg, Texas 78539
Texas Oncology - Fredericksburg
Fredericksburg, Texas 78624
Fredericksburg, Texas 78624
Texas Oncology - Harlingen
Harlingen, Texas 78550
Harlingen, Texas 78550
Texas Oncology McAllen
McAllen, Texas 78503
McAllen, Texas 78503
Texas Oncology, New Braunfels
New Braunfels, Texas 78130
New Braunfels, Texas 78130
Texas Oncology-San Antonio Cancer Care
San Antonio, Texas 78216
San Antonio, Texas 78216
Texas Oncology - San Antonio Northeast
San Antonio, Texas 78217
San Antonio, Texas 78217
Texas Oncology - San Antonio Stone Oak
San Antonio, Texas 78258
San Antonio, Texas 78258
Tranquil Clinical Research
Webster, Texas 77598
Webster, Texas 77598
Texas Oncology - Weslaco
Weslaco, Texas 78596
Weslaco, Texas 78596
Hematology-Oncology Associates of Fredericksburg, Inc
Fredericksburg, Virginia 22408
Fredericksburg, Virginia 22408
Cancer Care Northwest
Spokane Valley, Washington 99218
Spokane Valley, Washington 99218
Cancer Care Northwest-1 (601 S. Sherman)
Spokane, Washington 99202
Spokane, Washington 99202
Cancer Care Northwest_2 (605 E. Holland)
Spokane, Washington 99218
Spokane, Washington 99218
Sheboygan Cancer & Blood Specialists
Sheboygan, Wisconsin 53081
Sheboygan, Wisconsin 53081
More Details
- NCT ID
- NCT06072612
- Status
- Recruiting
- Sponsor
- BriaCell Therapeutics Corporation
Detailed Description
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available. A secondary objective will be to evaluate the activity of the Bria-IMT regimen alone in comparison with the Bria-IMT regimen in combination with CPI. Initial randomization will be 1:1:1 to the Bria-IMT regimen + CPI (combination therapy), TPC, and the Bria-IMT regimen alone (monotherapy). After the first 150 patients have enrolled in the study, the monotherapy arm will be discontinued and patients allowed to cross over to the combination therapy if needed. Randomization will continue 1:1 between the combination therapy vs TPC. For the Bria regimen +/- CPI arms, treatment cycles occur every 3 weeks. TPC cycle details will be according to the site's SOC. In the absence of progressive disease or major safety issues, the patient will continue with therapy cycles, with imaging assessment every 6 weeks x2 then every 8 weeks thereafter. The Bria-IMT regimen includes: Day -2 or -3 Cyclophosphamide 300mg/m2 Day 0 SV-BR-1-GM given intradermally divided into 4 inoculations Day 1-3 CPI infusion plus interferon intra-dermally within each Bria-IMT inoculation site